130 related articles for article (PubMed ID: 16289924)
1. Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB.
Sharma S; Dominguez AL; Lustgarten J
Exp Gerontol; 2006 Jan; 41(1):78-84. PubMed ID: 16289924
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
[TBL] [Abstract][Full Text] [Related]
3. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy.
Boczkowski D; Lee J; Pruitt S; Nair S
Cancer Gene Ther; 2009 Dec; 16(12):900-11. PubMed ID: 19498460
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
Cuadros C; Dominguez AL; Lollini PL; Croft M; Mittler RS; Borgström P; Lustgarten J
Int J Cancer; 2005 Oct; 116(6):934-43. PubMed ID: 15856473
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD137 monoclonal antibody promotes the direct anti-tumor effect mediated by peripheral blood-derived human dendritic cells in vitro.
Zhang L; Wang Q; Wang X; Ding P; Song J; Ma C; Sun W
Cell Mol Immunol; 2004 Feb; 1(1):71-6. PubMed ID: 16212924
[TBL] [Abstract][Full Text] [Related]
7. Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells.
Pilon-Thomas S; Verhaegen M; Kuhn L; Riker A; Mulé JJ
Cancer Immunol Immunother; 2006 Oct; 55(10):1238-46. PubMed ID: 16315029
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic vaccination with tumor cells that engage CD137.
Hellstrom KE; Hellstrom I
J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
[TBL] [Abstract][Full Text] [Related]
9. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.
Yasuda T; Kamigaki T; Kawasaki K; Nakamura T; Yamamoto M; Kanemitsu K; Takase S; Kuroda D; Kim Y; Ajiki T; Kuroda Y
Cancer Immunol Immunother; 2007 Jul; 56(7):1025-36. PubMed ID: 17131118
[TBL] [Abstract][Full Text] [Related]
10. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
12. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
13. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q
Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943
[TBL] [Abstract][Full Text] [Related]
14. A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model.
Jack AM; Aydin N; Montenegro G; Alam K; Wallack M
J Surg Res; 2007 May; 139(2):164-9. PubMed ID: 17275030
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.
Kocak E; Lute K; Chang X; May KF; Exten KR; Zhang H; Abdessalam SF; Lehman AM; Jarjoura D; Zheng P; Liu Y
Cancer Res; 2006 Jul; 66(14):7276-84. PubMed ID: 16849577
[TBL] [Abstract][Full Text] [Related]
16. Radiation-induced apoptosis along with local and systemic cytokine elaboration is associated with DC plus radiotherapy-mediated renal cell tumor regression.
Huang J; Wang Y; Guo J; Lu H; Lin X; Ma L; Teitz-Tennenbaum S; Chang AE; Li Q
Clin Immunol; 2007 Jun; 123(3):298-310. PubMed ID: 17449328
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with agonistic anti-CD137: two sides of a coin.
Sun Y; Chen JH; Fu Y
Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination.
Kuriyama H; Watanabe S; Kjaergaard J; Tamai H; Zheng R; Weinberg AD; Hu HM; Cohen PA; Plautz GE; Shu S
Cell Immunol; 2006 Sep; 243(1):30-40. PubMed ID: 17207783
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]